secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001159036-25-000047
Event type: debt
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme to offer $1.3B in convertible notes; extends credit facility to $750M
------------------------------------------------------------------------------

- Amended credit facility: commitments increased to $750M, maturity extended to Nov 5, 2030; no outstanding borrowings.
- Proposes $650M 2031 notes and $650M 2032 notes; option for additional $100M each.
- Net proceeds partly fund capped call transactions to reduce potential dilution upon conversion.
- Plans to repurchase existing 0.25% 2027 and 1.00% 2028 convertible notes via private deals.
- Remaining proceeds for general corporate purposes, including working capital and acquisitions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000047/0001159036-25-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000047/halo-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001159036-25-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer